Dubreuil P, Torrès H, Courcoul M A, Birg F, Mannoni P
INSERM, Marseille, France.
Blood. 1988 Sep;72(3):1081-5.
The c-fms protooncogene product was identified as the CSF-1 or M-CSF receptor, a polypeptide growth factor that plays a major role in myelomonocytic differentiation. This led us to look for expression of c-fms in fresh acute myeloid leukemia (AML) cells, using Northern blot analysis. c-fms expression was found in the leukemic cells of 28 AML patients, regardless of their stage of differentiation, which was assessed in the French-American-British (FAB) classification. However, the level of c-fms expression was especially high in AML of the M5 stage. High levels of expression were not accompanied by either amplification or rearrangements of the c-fms gene in AML cell DNAs. In contrast, c-fms expression was not found in acute lymphoid leukemias, whether of T or B origin. Thus, c-fms expression appears as a specific molecular marker of leukemogenesis in the myeloid lineage.
c-fms原癌基因产物被鉴定为集落刺激因子-1（CSF-1）或巨噬细胞集落刺激因子（M-CSF）受体，这是一种在髓单核细胞分化中起主要作用的多肽生长因子。这促使我们使用Northern印迹分析来寻找新鲜急性髓性白血病（AML）细胞中c-fms的表达情况。在28例AML患者的白血病细胞中发现了c-fms表达，无论其分化阶段如何，分化阶段是按照法美英（FAB）分类法评估的。然而，c-fms表达水平在M5期AML中尤其高。AML细胞DNA中c-fms基因的高水平表达并未伴随基因扩增或重排。相比之下，无论是T细胞来源还是B细胞来源的急性淋巴细胞白血病中均未发现c-fms表达。因此，c-fms表达似乎是髓系谱系白血病发生的特异性分子标志物。
